Abbott's xience stent receives fda approval for shortest blood thinner course for high bleeding risk patients

Abbott park, ill., june 30, 2021 /prnewswire/ -- abbott (nyse: abt) today announced its xience family of stents has received u.s. food and drug administration (fda) approval for one-month (as short as 28 days) dapt labeling for high bleeding risk (hbr) patients in the u.s. in addition, xience stents recently received ce mark approval for dapt as short as 28 days – giving xience stents the shortest dapt indication in the world.
ABT Ratings Summary
ABT Quant Ranking